Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients.

Trial Profile

Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Erlotinib (Primary) ; Sulindac (Primary)
  • Indications Familial adenomatous polyposis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2016 Status changed from active, no longer recruiting to completed according to results published in the Journal of the American Medical Association.
    • 22 Mar 2016 Primary endpoint of comparison of change in total duodenal and colorectal polyp burden at 6 months has been met, according to results published in the Journal of the American Medical Association.
    • 22 Mar 2016 Results published in the JAMA: the Journal of the American Medical Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top